Am J Transplant, Volume 5, Suppl 3 Archives - Page 168 of 170 - ATC Abstracts

2015 American Transplant Congress
Biomarkers of Deceased Donors for the Prediction of Renal Allograft Outcomes
S. Kang,¹ H. Im,¹ J. Lee,¹ T. Koo,¹ S. Lee,² S. Park,³ S.-J. Kim,⁴ C. Ahn,¹ J. Yang.¹
¹Transplantation Center, Seoul National University Hospital, Seoul, Republic of Korea; ²Chonbuk National University Hospital, Jeonju, Republic of Korea; ³Inje University Busan Paik Hospital, Busan, Republic of Korea; ⁴Samsung Medical Center, Seoul, Republic of Korea.
Background: Better prognostic markers in deceased donors(DD) are needed for determining whether to accept suboptimal DD kidneys or predicting post-transplant outcomes. Recently, neutrophil gelatinase-associated lipocalin(NGAL),…
2015 American Transplant Congress
CD28-Directed Therapy Prolongs Survival in a Non-Human Primate Kidney Transplant Model
L. Higginbotham,¹ D. Mathews,¹ C. Breeden,¹ W. Wakwe,¹ C. Larsen,¹ S. Nadler,² A. Adams.¹
¹Emory Transplant Center, Emory University School of Medicine, Atlanta; ²Bristol-Myers Squibb, Princeton.
Introduction. Costimulation blockade using belatacept has the potential to improve long-term renal function and reduce cardiovascular risk by avoiding calcineurin inhibitors, yet higher rates and…
2015 American Transplant Congress
Distinctive Roles of mTORC1 Vs. mTORC2 in Liver Ischemia-Reperfusion Injury
H. Zhou,^1,2 J. Zhu,^1,3 S. Yue,¹ M. Zhang,³ R. Busuttil,¹ Q. Xia,³ J. Kupiec-Weglinski,¹ Y. Zhai.¹
¹The Dumont-UCLA Transplant Center, UCLA, Los Angeles; ²Liver Transplant Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; ³Liver Surgery, Renji Hospital, Shanghai Jiaotong University, Shanghai, China.
Mammalian target of rapamycin (mTOR) exists in two complexes to regulate diverse biological processes. Although mTOR complex 1, the canonical target of rapamycin, has been…
2015 American Transplant Congress
Treatment of Hepatitis C Virus in Kidney Transplant Recipients With Direct Acting Anti-Viral Agents: Early Results in 12 Cases
A. Sharfuddin,¹ T. Taber,¹ M. Mujtaba,¹ M. Yaqub,¹ D. Mishler,¹ P. Kwo,² R. Vuppalanchi.²
¹Medicine/Nephrology, Indiana University, Indianapolis; ²Medicine/Hepatology, Indiana University, Indianapolis.
Background: Recently approved direct acting antiviral agents (DAA) for treatment of HCV are interferon sparing allowing an attractive treatment option for kidney transplant recipient with…
2015 American Transplant Congress
Complement Inhibition Via the Lectin Pathway Improves Experimental Cardiac Graft Survival
J. Kindermann,^1,2 M. Waechter,^1,2 R. Bruno,¹ M. Langenmayer,³ T. Dudler,⁴ W. Schwaeble,⁵ E. Kleinert,¹ T. Mayr,^1,2 H. Christian,² R. Wanke,³ J.-M. Abicht,⁶ S. Guethoff.¹
¹Transregio Collaborative Research Center 127, Ludwig-Maximilians University, Munich, Germany; ²Department of Cardiac Surgery, Ludwig-Maximilians University, Munich, Germany; ³Institute of Veterinary Pathology, Ludwig-Maximilians University, Munich, Germany; ⁴Omeros Corporation, Seattle, WA; ⁵Department of Infection, Immunity, and Inflammation, Leicester University, Leicester, United Kingdom; ⁶Department of Anaesthesiology, Ludwig-Maximilians University, Munich, Germany.
Purpose: While complement activation via both the classical as well as the lectin pathway is believed to contribute to allograft loss, their relative contribution is…
2015 American Transplant Congress
Evaluation of Leflunomide for the Treatment of BK Viremia and Biopsy Proven BK Nephropathy: A Single Center Experience
N. Nesselhauf,¹ J. Strutt,² B. Bastani.¹
¹Saint Louis University Hospital, St. Louis, MO; ²Minneapolis VA Health Care System, Minneapolis, MN.
Purpose:The objective was to evaluate the use of leflunomide in BK viremia (BKV) and biopsy proven BK nephropathy (BKN) in kidney and kidney-pancreas transplant recipients.Methods:We…
2015 American Transplant Congress
A Relative Survival Model to Compare the Risk of Mortality in Patients Awaiting Kidney Transplantation Versus Already Transplanted Patients
M. Lorent,^1,2 K. Trébern-Launay,^2,1 C. Legendre,⁴ H. Kreis,⁴ G. Mourad,⁵ V. Garrigue,⁵ L. Rostaing,⁶ N. Kamar,⁶ M. Kessler,⁷ M. Ladrière,⁷ E. Morelon,⁸ F. Buron,⁸ M. Giral,^2,3 Y. Foucher.^1,2
¹EA 4275 - SPHERE bioStatistics, Pharmacoepidemiology and Human Sciences Research, Nantes University, Nantes, France; ²Institut de Transplantation, Urologie, Néphrologie (ITUN), Inserm U1064, CHU de Nantes, Nantes, France; ³CIC Biotherapy, CHU Nantes, Nantes, France; ⁴Service de Transplantation Rénale et de Soins Intensifs, Hôpital Necker, APHP Paris, Paris, France; ⁵Service de Néphrologie-Transplantation, Hôpital Lapeyronie, Montpellier, France; ⁶Service de Néphrologie, HTA, Dialyse et Transplantation d'Organes, CHU Rangueil, Toulouse, France; ⁷Service de Transplantation Rénale, CHU Brabois, Nancy, France; ⁸Service de Néphrologie, Transplantation et Immunologie Clinique, Hôpital Edouard Herriot, Lyon, France.
Introduction: It would be useful for physicians in some specific cases to identify whom patients could not benefit of kidney transplantations.Patients and method: To answer…
2015 American Transplant Congress
Is Organ Transplantation from Trypanosoma cruzi-Infected Donors Safe? An Autopsy-Based Study of Parasite Persistence in Chronic Chagasic Patients
L. Benvenuti, A. Roggério.
Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil.
Introduction: Chagas' disease, endemic in Latin America, is caused by infection with the protozoan Trypanosoma cruzi. The disease can affect the heart and/or the gastrointestinal…
2015 American Transplant Congress
A Prospective Pilot Study Evaluating the Safety and Efficacy of Everolimus for the Prevention of CMV and BK Viral Infection (BKV) in Broadly Sensitized Kidney Transplant Recipients Following Desensitization With IVIG and Rituximab: Interim Analysis
J. Kahwaji,¹ S. Louie,¹ A. Vo,¹ J. Choi,¹ M. Toyoda,² S. Ge,² P. Wongsaroj,¹ A. Peng,¹ R. Villicana,¹ S. Jordan.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Transplant Immunology Lab, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: Everolimus, a second generation mTOR inhibitor, may prevent CMV and BKV infection after kidney transplantation. Broadly sensitized patients are at greater risk of viral…
2015 American Transplant Congress
Outcomes of Eculizumab (ANTI-C5) Therapy for Treatment of Refractory Antiobdy-Mediated Rejection (ABMR) and Thrombotic Microangiopathy (TMA)
P. Wongsaroj,¹ J. Choi,¹ A. Vo,¹ J. Kahwaji,¹ A. Peng,¹ R. Villicana,¹ M. Haas,² S. Jordan.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Pathology, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: ABMR results from DSA binding to donor endothelium initiating the classical complement pathway. This results in the formation of terminal MAC (C5b-C9) complex and…